Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.72 is in line with its 5-year average of -2.61, around the middle of its 5-year range (-3.12–-2.12).
0.74% below its 12-month average of -2.70.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.04.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 29 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.72
EARNINGS PER SHARE (EPS) AVG TTM
-2.70
EARNINGS PER SHARE (EPS) AVG 3Y
-2.77
EARNINGS PER SHARE (EPS) AVG 5Y
-2.61
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-0.74%
CURRENT VS 3Y AVG
+1.98%
CURRENT VS 5Y AVG
-4.08%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$670.70M
Earnings Per Share (EPS)
-2.72
TTM Avg
-2.70
3Y Avg
-2.77
5Y Avg
-2.61
Market Cap
$669.77M
Earnings Per Share (EPS)
0.04
TTM Avg
0.31
3Y Avg
0.21
5Y Avg
0.05
Market Cap
$677.18M
Earnings Per Share (EPS)
-5.51
TTM Avg
-4.06
3Y Avg
-4.55
5Y Avg
-6.70
Market Cap
$678.13M
Earnings Per Share (EPS)
-1.16
TTM Avg
-1.18
3Y Avg
-1.68
5Y Avg
-2.29
Market Cap
$657.45M
Earnings Per Share (EPS)
-0.36
TTM Avg
-0.59
3Y Avg
-0.49
5Y Avg
-0.39
Market Cap
$684.72M
Earnings Per Share (EPS)
-1.91
TTM Avg
-2.52
3Y Avg
-4.99
5Y Avg
-9.27
Market Cap
$690.35M
Earnings Per Share (EPS)
-2.76
TTM Avg
-3.16
3Y Avg
-2.11
5Y Avg
-1.54
Market Cap
$705.61M
Earnings Per Share (EPS)
-3.68
TTM Avg
-3.44
3Y Avg
-2.54
5Y Avg
-10.12
Market Cap
$635.27M
Earnings Per Share (EPS)
-1.78
TTM Avg
-1.75
3Y Avg
-1.85
5Y Avg
-1.69
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $670.70M | -2.72 | -2.70 | -2.77 | -2.61 |
| MiMedx Group, Inc. (MDXG)vs › | $669.77M | 0.04 | 0.31 | 0.21 | 0.05 |
| Helus Pharma Inc. (HELP)vs › | $677.18M | -5.51 | -4.06 | -4.55 | -6.70 |
| Annexon, Inc. (ANNX)vs › | $678.13M | -1.16 | -1.18 | -1.68 | -2.29 |
| OmniAb, Inc. (OABI)vs › | $657.45M | -0.36 | -0.59 | -0.49 | -0.39 |
| Solid Biosciences Inc. (SLDB)vs › | $684.72M | -1.91 | -2.52 | -4.99 | -9.27 |
| Anteris Technologies Global Corp. (AVR)vs › | $690.35M | -2.76 | -3.16 | -2.11 | -1.54 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $705.61M | -3.68 | -3.44 | -2.54 | -10.12 |
| Aura Biosciences, Inc. (AURA)vs › | $635.27M | -1.78 | -1.75 | -1.85 | -1.69 |
| Climb Bio, Inc. (CLYM)vs › | $632.18M | -0.83 | -1.21 | -1.36 | -1.94 |
Trailing EPS (TTM)
$-2.72
Forward EPS (Est.)
$-4.14
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.42 |
| 2024-12-31 | -2.98 |
| 2023-12-31 | -2.58 |
| 2022-12-31 | -3.12 |
| 2021-12-31 | -2.46 |
| 2020-12-31 | -2.12 |
| 2019-12-31 | -2.00 |
| 2018-12-31 | -0.76 |
| 2017-12-31 | -0.76 |
